Additional file 1 of Identification of tumor antigens and anoikis-based molecular subtypes in the hepatocellular carcinoma immune microenvironment: implications for mRNA vaccine development and precision treatment

Additional file 1: Figure S1. Identification of tumor antigen genes associated with HCC prognosis in TCGA and meta cohorts. The KM curve of the overall survival for different group with different expression of (A) AURKA. (B) CCNB1. (C) CDK1. (D) KPNA2. (E) PRC1. (F) PTTG1. (G) UBE2S in TCGA cohorts. The KM curve of the disease free survival for different group with different expression of (H) AURKA. (I) CCNB1. (J) CDK1. (K) KPNA2. (L) PRC1. (M) PTTG1. (N) UBE2S in TCGA cohorts. The KM curve of the overall survival for different group with different expression of (O) AURKA (P) CCNB1 (Q) CDK1 (R) KPNA2 (S) PTTG1 (T) UBE2S in meta cohorts (TCGA + GEO). Figure S2. Antigten correlation Analysis of the Immune Microenvironment of Seven Potential Tumor Antigens, including tumor purity, B cell, CD8 + T cell, CD4 + T cell, Macrophage, Neutrophil, Dentritic cell. (A) AURKA. (B) CCNB1. (C) CDK1. (D) KPNA2. (E) PRC1. (F) PTTG1. (G) UBE2S. Figure S3. OS analysis for 28 Anoikis-related genes. Figure S4. PCA analysis for four cohorts. (A) PCA analysis of all genes in the TCGA cohort. (B) PCA analysis of anoikis-related genes in the TCGA cohort. (C) PCA analysis of anoikis-related lncRNAs in the TCGA cohort. (D) PCA analysis of anoikis-related risk lncRNAs in the TCGA cohort. Figure S5. (A) Forest plot of univariate analysis with risk score. (B) Forest plot of multivariate analysis with risk score. Figure S6. Survival curves of different clinical feature subgroups under ARG score for (A) patients with age > 65 years (B) patients with age <  = 65 (C) female patients subgroup (D) female patients subgroup (E) patients with G1-G2 subgroup (F) patients with G3-G4 subgroup (G) patients with M0 subgroup (H) patients with M1 subgroup (I) patients with Mx subgroup (J) patients with N0 subgroup (K) patients with Stage I subgroup (L) patients with Stage II subgroup (M) patients with Stage III-IV subgroup (N) patients with T1 subgroup (O) patients with T2 subgroup (P) patients with T3-T4 subgroup. Figure S7. The immune microenvironment analysis of high and low ARI score group in HCC. (A) ESTIMATEScores, (B) ImmuneScores, (C) StromalScores and (D) TumorPurity. Figure S8. Sensitivity for 16 representative chemotherapeutic agents based on ARI score.